Similarly, the model integrating GAS5 loss offers the highest clinical benefit for the prediction of NMIBC progression for threshold probabilities >0%, compared to tumour stage, grade, EORTC-risk group and recurrence at FFC model (Fig. 6b). This evidence concerns the gene GAS5 and neoplasm.